Diligence memo · auto-generated · as of July 2, 2026
Nupathe Inc.
Nupathe Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Nupathe Inc. operates in Pharmaceuticals, based in CONSHOHOCKEN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nupathe Inc. has raised $39M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $28M on 2012-10-23.
Most recent recorded round closed around 2012-10-23.
Valuation (modeled)modeled
Provath models Nupathe Inc. at approximately $952M (range $59M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.29× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era. Within the normal band (129% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 13.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 25.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 77% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 88% of those peers.
Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, Pernix Therapeutics Holdings, Inc., CEBIX Inc.
Peoplefiled
23 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.